Otonomy, Inc. Logo
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
May 04, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy, Inc. Logo
Otonomy Announces Pricing of $30.1 Million Public Offering
April 07, 2021 22:02 ET | Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Proposed Public Offering
April 07, 2021 16:06 ET | Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
March 25, 2021 07:30 ET | Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
Otonomy, Inc. Logo
Otonomy to Participate in Three Upcoming Investor Conferences
February 25, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
February 22, 2021 07:00 ET | Otonomy, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
February 17, 2021 07:30 ET | Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 11, 2021 16:17 ET | Otonomy, Inc.
OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...
Otonomy, Inc. Logo
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
February 04, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...